Skip to main content
SpringerLink
Log in

Betarezeptorenblocker

  • Chapter
Arzneiverordnungs-Report 2015

  • 1928 Accesses

Zusammenfassung

Betarezeptorenblocker spielen eine wichtige Rolle bei der Behandlung kardiovaskulärer Krankheiten. Hauptindikationen sind arterielle Hypertonie, koronare Herzkrankheit, tachykarde Herzrhythmusstörungen und chronische Herzinsuffizienz. Wichtigste Gruppe sind die β1-selektiven Betarezeptorenblocker.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Aursnes I, Osnes J-B, Tvede IF, Gasemyr J, Natvig B (2007): Does atenolol differ from other ß-adrenergic blockers? BMC Clin Pharmacol 7:4

    Article  PubMed Central  PubMed  Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2009): 23. Arterielle Hypertonie: Arzneiverordnungen. 22. Aufl., Medizinische Medien Informations GmbH, Neu-Isenburg: S 597628

    Google Scholar 

  • Barron AJ, Zaman N, Cole GD, Wensel R, Okonko DO, Francis DP (2013): Sytematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. Int J Cardiol 168: 3572–3579

    Article  PubMed Central  PubMed  Google Scholar 

  • Beevers DG (2005): The end of beta blockers for uncomplicated hypertension? Lancet 366: 1510–1512

    Article  PubMed  Google Scholar 

  • Bell DS, Lukas MA, Holdbruck FK, Fowler MB (2006): The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. Curr Med Res Opin 22: 287–296

    Article  CAS  PubMed  Google Scholar 

  • Bowman AJ, Chen CP, Ford GA (1994): Nitric oxide mediated venodilator effects of nebivolol. Brit J Clin Pharmacol 38: 199–204

    Article  CAS  Google Scholar 

  • Chatterjee S, Biondi-Zoccai G, Abbate A, D'Ascenzo F, Castagno D, Van Tassell B, Mukherjee D, Lichstein E (2013): Benefits of ß blockers in patients with heart failure and reduced ejec- tion fraction: network meta-analysis. BMJ 346: f596

    Google Scholar 

  • Chobanian AV, et al (2003): Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute;. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7). JAMA 289: 2560-72. Erratum in: JAMA 2003, 920:19–7

    Google Scholar 

  • CIBIS II Study (1999): The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. Lancet 353: 9–13

    Article  Google Scholar 

  • Contini M, Apostolo A, Cattadori G, Paolillo S, Iorio A, Bertella E, Salvioni E, Alimento M, Farina S, Palermo P, Louercio M, Manzegazza V, Karten M, Sciomer, S, Magri D, Fiorentini C, Agpstini P (2013). Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: The CARNEBI trial. Int J Cardiol 168: 2134–2140

    Article  PubMed  Google Scholar 

  • Dargie HJ (2003): ß-Blockers in heart failure. Lancet 362: 2–3

    Article  PubMed  Google Scholar 

  • Deutsche Hochdruckliga - Deutsche Hypertonie Gesellschaft (2008): Leitlinien zur Behandlung der arteriellen Hypertonie. Stand Juni 2008. http: //www.leitlinien.net'046-001.pdf

    Google Scholar 

  • Deutsche Hochdruckliga, Deutsche Gesellschaft für Hypertonie und Prävention. (2011). DHL- Leitlinien-update 2011. http://www.hochdruckliga.de/tl_files/content/dhl/downloads/DHL-Leitlinien-2011.pdf

  • DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH (2013). Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol). Am J Cardiol 111: 765–769

    Article  CAS  PubMed  Google Scholar 

  • DiNIcolantonio JJ, Fares H, Niazi AK, et al. (2015): ß-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the Literature. Open Heart 21(1): e00023–0

    Google Scholar 

  • Eschenhagen T, Erdmann E (2010): 16. Herzinsuffizienz. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie - Klinische Pharmakologie, 14. Auflage, Springer, Heidelberg New York, S. 22924–3

    Google Scholar 

  • Flather MC, Shibata MC, Coats AJS et al (2005): Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26: 215–225

    Article  CAS  PubMed  Google Scholar 

  • Grundt C, Meier K, Grundt A, Lemmer B (2007): Evidence for an estradiol-agonistic action of nebivolol in spontaneously hypertensive rats. J Hypertens 25: 1001–1007

    Article  CAS  PubMed  Google Scholar 

  • Hohlfeld T, Kelm M (2010): 17. Koronare Herzkrankheit. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie - Klinische Pharmakologie, 14. Auflage, Springer, Heidelberg New York, S. 245–257

    Google Scholar 

  • Hoppe UC, Erdmann E (2010): Herzinsuffizienz Update 2010 und aktuelle ESC-Leitlinien. Herz 35:535–541

    Article  CAS  PubMed  Google Scholar 

  • Kintscher U, Böhm M, Goss F, Kolloch R, Kreutz R, Schmieder R, Schunkert H (2014): Kommentar zur 2013-ESH/ESC-Leitlinie zum Management der arteriellen Hypertonie. Kardiologie 8:223–230

    Article  CAS  Google Scholar 

  • Kreutz R, Kolloch R (2010): Arterielle Hypertonie. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie - Klinische Pharmakologie, 14. Auflage, Springer Verlag, Berlin Heidelberg New York, S. 197–218

    Google Scholar 

  • Leaute-Labreze C, Hoeger P, Mazereew-Hautier J, et al. (2015): A randomized, controlled trial of propranolol in infantile hemangioma. N Eng J Med 19:735–746

    Article  Google Scholar 

  • Lindholm LH, Carlberg B, Samuelsson O (2005): Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366: 1545–1553

    Article  CAS  PubMed  Google Scholar 

  • McMurray J (2005): Making sense of SENIORS. Eur Heart J 26: 203–206

    Article  CAS  PubMed  Google Scholar 

  • MERIT-HF Study (1999): Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure. Lancet 353: 2001–2007

    Article  Google Scholar 

  • Moen MD, Wagstaff AJ (2006): Nebivolol - a review of its use in the management of hypertension and chronic heart failure. Drugs 66: 1389–1409

    Article  CAS  PubMed  Google Scholar 

  • National Institute for Health and Care Excellence (NICE) (2011): Hypertension - Clinical

    Google Scholar 

  • management of primary hypertension in adults. Issued: August 2011 .NICE clinical guide- line 127: Internet: guidance.nice.org.uk/cg127

    Google Scholar 

  • Nationale VersorgungsLeitlinie (2013): Chronische Herzinsuffizienz. http://www.leitlinien.de/>nvl/herzinsuffizienz

  • Packer M, Coats AJS, Fowler MB, Katus HA et al (2001): Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344: 1651–1658

    Article  CAS  PubMed  Google Scholar 

  • Poole-Wilson PA, Svedberg K, Cleland JGF, Lenarda A, Hanrath P, Komajda M et al (2003): Com- parison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362: 7–13

    Article  CAS  PubMed  Google Scholar 

  • POISE Study Group (2008): Effects of extended-release metoprolol succinate in patients under- going non-cardiac surgery (POISE trial) a randomized controlled trial. Lancet 371: 1839184–7

    Google Scholar 

  • Sackner-Bernstein J (2005): Reducing the risks of sudden death and heart failure post myo- cardial infarction: utility of optimized pharmacotherapy. Clin Cardiol 28 (11 Suppl 1): I19–27

    Google Scholar 

  • Salpeter S, Ormiston T, Salpeter E, Wood-Baker R (2006): Cardioselective beta-blockers for reversible airway disease. The Cochrane Library, The Cochrane Collaboration Volume (1), 2006

    Google Scholar 

  • Tzemos N, Lim PO, MacDonald TM (2001): Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 104: 511–514

    Article  CAS  PubMed  Google Scholar 

  • Vestbo J, Hurd SS, Augusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Mar- tinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. (2013). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. Am J Respir Crit Care Med. 187: 347–365

    Article  CAS  PubMed  Google Scholar 

  • Wiysonge CS, Bradley HA, J V, Mayosi MB, Mbewu A, Opie LH. (2012). Beta-blockers for hypertension. Cochrane Database Syst Rev. Nov 14: CD00200–3

    Google Scholar 

Download references

Authors
  1. Björn Lemmer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2015 Springer-Verlag Berlin Heidelberg

    About this chapter

    Cite this chapter

    Lemmer, B. (2015). Betarezeptorenblocker. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2015. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-47186-9_17

    Download citation

    • DOI: https://doi.org/10.1007/978-3-662-47186-9_17

    • Publisher Name: Springer, Berlin, Heidelberg

    • Print ISBN: 978-3-662-47185-2

    • Online ISBN: 978-3-662-47186-9

    • eBook Packages: Medicine (German Language)

    Publish with us

    Policies and ethics

    Search

    Navigation